Knight Therapeutics
Market Cap
CA$739.9m
Last Updated
2021/01/21 23:52 UTC
Data Sources
Company Financials +
Executive Summary
Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. More Details
Rewards
Risk Analysis
Earnings are forecast to decline by an average of 1.2% per year for the next 3 years
Snowflake Analysis
Fair value with acceptable track record.
Similar Companies
Share Price & News
How has Knight Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GUD is less volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: GUD's weekly volatility (3%) has been stable over the past year.
Market Performance
7 Day Return
5.0%
GUD
3.0%
CA Pharmaceuticals
0.7%
CA Market
1 Year Return
-29.3%
GUD
49.4%
CA Pharmaceuticals
2.1%
CA Market
Return vs Industry: GUD underperformed the Canadian Pharmaceuticals industry which returned 52.2% over the past year.
Return vs Market: GUD underperformed the Canadian Market which returned 2% over the past year.
Shareholder returns
| GUD | Industry | Market | |
|---|---|---|---|
| 7 Day | 5.0% | 3.0% | 0.7% |
| 30 Day | 3.1% | 32.8% | 4.6% |
| 90 Day | -0.7% | 71.2% | 13.5% |
| 1 Year | -29.3%-29.3% | 49.4%49.4% | 5.8%2.1% |
| 3 Year | -26.1%-26.1% | -51.7%-52.4% | 13.9%3.1% |
| 5 Year | -15.3%-15.3% | 413.7%410.0% | 67.3%41.6% |
Long-Term Price Volatility Vs. Market
How volatile is Knight Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall St
Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story?2 weeks ago | Simply Wall St
What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares?1 month ago | Simply Wall St
A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)Valuation
Is Knight Therapeutics undervalued compared to its fair value and its price relative to the market?
10.8%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: GUD (CA$5.69) is trading below our estimate of fair value (CA$6.34)
Significantly Below Fair Value: GUD is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: GUD is good value based on its PE Ratio (27.9x) compared to the CA Pharmaceuticals industry average (31x).
PE vs Market: GUD is poor value based on its PE Ratio (27.9x) compared to the Canadian market (16.8x).
Price to Earnings Growth Ratio
PEG Ratio: GUD's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: GUD is good value based on its PB Ratio (0.8x) compared to the CA Pharmaceuticals industry average (2.8x).
Next Steps
Future Growth
How is Knight Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
-1.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GUD's earnings are forecast to decline over the next 3 years (-1.2% per year).
Earnings vs Market: GUD's earnings are forecast to decline over the next 3 years (-1.2% per year).
High Growth Earnings: GUD's earnings are forecast to decline over the next 3 years.
Revenue vs Market: GUD's revenue (7.9% per year) is forecast to grow faster than the Canadian market (7.9% per year).
High Growth Revenue: GUD's revenue (7.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GUD's Return on Equity is forecast to be low in 3 years time (5.7%).
Next Steps
Past Performance
How has Knight Therapeutics performed over the past 5 years?
-28.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GUD has high quality earnings.
Growing Profit Margin: GUD's current net profit margins (15%) are lower than last year .
Past Earnings Growth Analysis
Earnings Trend: GUD's earnings have declined by 28.3% per year over the past 5 years.
Accelerating Growth: GUD's earnings growth over the past year (27.3%) exceeds its 5-year average (-28.3% per year).
Earnings vs Industry: GUD earnings growth over the past year (27.3%) exceeded the Pharmaceuticals industry -61.1%.
Return on Equity
High ROE: GUD's Return on Equity (2.3%) is considered low.
Next Steps
Financial Health
How is Knight Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: GUD's short term assets (CA$540.6M) exceed its short term liabilities (CA$99.0M).
Long Term Liabilities: GUD's short term assets (CA$540.6M) exceed its long term liabilities (CA$32.7M).
Debt to Equity History and Analysis
Debt Level: GUD's debt to equity ratio (4.9%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if GUD's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: GUD's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if GUD's interest payments on its debt are well covered by EBIT.
Balance Sheet
Next Steps
Dividend
What is Knight Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GUD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GUD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GUD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GUD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GUD's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.4yrs
Average management tenure
CEO
Jonathan Goodman (51 yo)
no data
Tenure
CA$1,125,744
Compensation
Mr. Jonathan Ross Goodman, BA, LLB, MBA founded Knight Therapeutics Inc. in February 2014 and serves as its Chief Executive Officer. Mr. Goodman has been Director at Endo International plc since December 2...
CEO Compensation Analysis
Compensation vs Market: Jonathan's total compensation ($USD890.42K) is about average for companies of similar size in the Canadian market ($USD790.55K).
Compensation vs Earnings: Jonathan's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | no data | CA$1.13m | 17.05% CA$ 126.1m | |
| President & Director | 4.42yrs | CA$987.14k | 0.037% CA$ 275.4k | |
| Chief Financial Officer | 0.83yr | CA$590.74k | 0.0054% CA$ 39.7k | |
| Vice President of Business Development | 6.42yrs | CA$749.51k | 0.088% CA$ 652.6k | |
| Senior Director of Business Development | no data | CA$315.32k | no data | |
| President of Knight Barbados | no data | CA$251.51k | no data |
4.4yrs
Average Tenure
Experienced Management: GUD's management team is considered experienced (4.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | no data | CA$1.13m | 17.05% CA$ 126.1m | |
| President & Director | 4.42yrs | CA$987.14k | 0.037% CA$ 275.4k | |
| Independent Chairman | no data | CA$95.34k | 0.039% CA$ 290.5k | |
| Independent Director | 7yrs | CA$93.62k | 0.051% CA$ 373.9k | |
| Independent Director | 0.58yr | no data | no data | |
| Independent Director | 0.58yr | no data | 0.0018% CA$ 13.1k | |
| Independent Director | 1.67yrs | CA$69.40k | no data |
3.0yrs
Average Tenure
52yo
Average Age
Experienced Board: GUD's board of directors are considered experienced (3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: GUD insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Knight Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Knight Therapeutics Inc.
- Ticker: GUD
- Exchange: TSX
- Founded: 2013
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$739.924m
- Shares outstanding: 130.04m
- Website: https://www.gud-knight.com
Number of Employees
Location
- Knight Therapeutics Inc.
- 3400 De Maisonneuve Boulevard West
- Suite 1055
- Montreal
- Quebec
- H3Z 3B8
- Canada
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| GUD | TSX (The Toronto Stock Exchange) | Yes | Common Shares | CA | CAD | Mar 2014 |
| KHTR.F | OTCPK (Pink Sheets LLC) | Yes | Common Shares | US | USD | Mar 2014 |
| 04K | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Mar 2014 |
Biography
Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distribu...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/21 23:52 |
| End of Day Share Price | 2021/01/21 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.